3rd Pharmaceutical & Biotechnology Pioneer Forum 2010 (PBPF2010)

 Exploring the new R&D metrics in post-blockbuster era

 Adapting to China’s evolving pharmaceutical and biotech/bioservice market

 Venturing into new scientific and therapeutic areas such as next generation antibody therapies and more

 Examining the latest trends in partnering and licensing deals in specialty markets such as China

 Creating successful M&A and strategic alliances in global partnerships and capturing the anticipated value

 Screening, evaluating, negotiating and implementing the right external innovation opportunities

 Unlocking value of co-development, co-commercialization and clinical trial opportunities

 One-on-one business meeting based on WISHING LIST, taking away with latest edition CRO booklet

 

The new healthcare reform has put China in the spotlight. China's pharmaceutical market capacity is projected to exceed 310 billion RMB by 2011 and $220 billion by 2020, overtaking France, Germany, Japan to become the second largest

 following the United States. The Chinese central government continues to push through reform and encourage pharmaceutical innovation to meet healthcare demand growth. The preferential drug pricing policies for innovative drugs and tax incentives

also suppot China in becoming a world R&D base. China is uniquely positioned to compete in the global innovative medicines industry.

 

China’s biopharma industry is entering its “Golden Age” and the primary drivers will be antibodies, vaccine and protein therapeutics. In June 2009, the State Council issued several policies of accelerating the development of bio industry in China and pointed out that the biopharma field is the vital one for the development of modern biotechnology. NDRC arranged additional 442 million yuan RMB central investment to support biological medicine, bio-breeding, the construction of special biomedical engineering high-tech industrialization project and special construction project of national biological industry base conditions for public service. The Chinese central government plans to continue investments in the biopharma sector to help it become one of the leading industries in China by 2020. 

 

Rising Licensing & External Innovation Partnership Opportunities  

New drug discovery is increasingly important, but the R&D process has never been more complex. Big pharma's thirst for external innovation is set to persist amidst the blockbuster drought. Also global economics, market pressures from payors and patients and a need to reduce internal infrastructure costs are forcing pharmaceutical companies to seek more international technology transfer and cross-border licensing opportunities. Technology transfer, especially licensing and cooperative development, has become a vital business development strategy for pharma industry. The Chieese Government is also making great efforts to support technology transfer and promote technological innovation. The Provisions for Registration of Drug Technology Transfer effect from August 19, 2009 will bring along a new wave of technology transfer in China.

 

Growing importance of CROs  

Bioservice is another fast-rising segment in the Chinese biopharma industry. Currently there are several hundred CROs operating in China offering integrated or specialized services and China's CROs devoted to late-stage research will boom along at an 18% annual growth rate, with revenue projected to grow from $145 million to $240 million by 2012. Increasingly, CROs are evolving from one-off study vendors to become viable, strategic long-term partners in tune with the goals and objectives for companies both big (to help improve productivity) and small (to help maximize licensing opportunities by achieving proof-of-concept without high infrastructure costs). The role of CROs as a regulatory resource has also grown significantly due to the current regulatory landscape in China.

 

Although the Chinese Government is taking initiatives to create a regulated market for fair competition of generics and innovative medicines, China’s pharmaceutical market is still generics dominated with over 5,000 generic companies. Expiring patents are even a bitter pill for big pharmas. A record number of drug patents will expire over the next few years, which should heighten competition from generic drugs and force down prices. In 2011, $58 billion of sales are at risk from patent expiries. 

 

Centered around the topic of "New R&D Metrics", PBPF2010 will track various focus points on open innovation and licensing opportunities, preclinical and clinical developments, RNAi, antibody and protein therapeutics, and point to the best opportunities for R&D partnering, providing you with the unique platform to review, examine and take advantage of these key issues. It will also help to fuel your company’s dynamic growth in China.

07:30   Registration – Coffee & Tea

08:30   Chairman’s Opening Address: US-China,  A Unique Opportunity for Bio-pharmaceutical Development

09:00    Opening Keynote Speech: Meeting Future Medical Needs with Open Innovation

09:45    Keynote Presentation: Screening, Evaluating, Negotiating and Implementing the Right External  

             Growth Opportunities

10:30    Coffee & Refreshments -- Speed Networking Break

             Meet... Move on... meet... move on... meet!

             Exchange business cards with fellow forum participants and industry peers

             Don’t forget to bring lots of business cards, a box or two will do!

11:00    Keynote Presentation: Accelerating Cancer Research in Asia through External Innovation &

             Partnership:

11:45    Managing IP in External Innovation Partnerships and Licensing

12:30    Luncheon

 

14:00  Government Special Address: What Should Domestic and MNC Pharmaceutical Companies Know

           about China’s  New Drug Registration Regulations?

14:30  Innovation Partnering in Asia: Aligning with the Changing Pharma/Biotech Landscape

15:00  New Dynamics of Strategic Alliances in Asia: Where are Big Pharmas all Going?

15:30  How Japanese Big Pharmas Restore Robust Growth by Implementing Overseas M&A and Licensing

           Strategies?

16:00  Coffee & Refreshments

           --One-on-one business meetings based on your WISHING LIST 

16:30  Co-Development of Novel Therapeutic Products in China

           -- A Chinese Biotech Company’s Partnering Perspective

17:00 Gaining a Clearer Perspective into Partnering & Licensing Opportunities of Therapeutic Antibodies for

          Cancer

17:30  Case Study of Bayer Schering Pharma’s Early Stage Partnering Strategy

18:00  Chairman’s Closing Remarks

18:10  Luxury Cocktail Party

  

08:00  Registration – Coffee & Tea

08:45  Chairman’s Welcome Address

09:00  What are the Challenges and Opportunities of Antibody Drug R&D and Commercialization in China?

09:30  Emerging Opportunities for the Treatment of Chronic Diseases

10:00  Keeping Abreast with Fully Human Monoclonal Antibody Technology Advancements

10:30  Coffee & Refreshments -- One-on-one business meetings based on your WISHING LIST

11:00  Interactive Panel Discusstion:

           --Next Generation Antibody Therapies - How Emerging Technologies Will Transform Antibody R&D

12:00  New Frontiers in Biomarker and Drug Development

12:30  Luncheon

 

14:00  Pharma - CRO Strategic Dialogue I:

          --How to Effectively Rise to Innovative Drug Discovery and Preclinical Development Challenges?

14:45  Translational Medicine: Accelerating Compounds to the Clinic 

15:15  Pharma - CRO Strategic Dialogue II:

           --21st Century Medcines and the Personalized Medicine Opportunity

16:00  Coffee & Refreshments -- One-on-one business meetings based on your WISHING LIST

16:30   Personalized Therapies and Best Clinical Practices for Lung Cancer

17:00   Pharma - CRO Strategic Dialogue III:

           -- Key Success Factors for Conducting Oncology Clinical Trials in Asia

17:45   Chiarman’s closing remarks

18:00   End of PBPF2010

PBPF2010 offers a number of sponsorship and exhibiting opportunities you can choose from to meet your goals before, during and after the event. If you would like to stand out from your competitors and outpace regional competition, you might leverage on highly targeted marketing, and we could roll out the tailor-made sponsorship package for you with the services you require. Sponsorship/exhibiting opportunities include: presentation sponsors,  exhibition sponsors, site-tour sponsors, cocktail, luncheon, coffee break sponsors, landyard sponsor, documentation bag sponsor, WISHING LIST sponsor and more.

 

Presidents, Vice Presidents, Directors, Senior Managers, Managers and Scientific Officers in charge of:

 Global Licensing / Business Development / Corporate Strategy / Strategic Alliance / Mergers and Acquisitions

 Research & Development / External Innovation / External Research / Global Sourcing

 Clinical Trials / Pre-clinical Development

 Intellectual Property & Patents

 Sales and Marketing

Abbott | ADICON Clinical Laboratories,Inc. | Alltrust Insurance Company of China Limited | Alpha & Omega B.V. | APBN | Apothecaries Clinical Research, India | Arsenal Capital Partners | Asia Global Research Co.,Ltd. | AsiaVest Partners, TCW/YFY Ltd. | AstraZeneca | AstraZeneca Investment (China) Co.,Ltd | Baycity Capital | Bayer Group Companies, Greater China | BEATRICE PEROTTI, INC. | Beijing Best Investment Co.,Ltd (Jiangxi JIMIN) | Beijing DMS Pharma Ltd., | Beijing Investment Promotion Bureau | BioCore Co.,Ltd. | BioDuro (Beijing) Co., Ltd | Bio-Rad Laboratories (Shanghai) | Bridge Biotech Park | Bridge Laboratories | Bristol-Myers Squibb | Cabinet | Changsha National Biomedical Industrial Base | Chem On Inc. | China Biotechnology | China Jianyin Investment Securities Co., Ltd. | China Prescription Drug | China Quality Mark Certification Group | Chinese Journal of Pharmaceuticals | Chinese-American BioMedical Association (CABA) | Chugai Pharma (Shanghai) Consulting Co., Ltd. Beijing Branch | Chugai Pharmaceutical Co., Ltd. | Contract Research Organization Union | China Association for Pharmaceuticals and Medical Technology | Corning China (Shanghai) Regional Headquarter | Corning China (Shanghai) Regional Headquarter, Beijing Branc | Covance Inc | CSSD | Curis | Da An Gene Co., Ltd. | Daiichi Sankyo Co.,Ltd | Dalian Economic & Technical Development Area，Science & Technology Bureau | Dalian Hi-tech Holdings Co.,LTD | Eisai Co.,Ltd | Eli Lilly and Company | EPS Internatiopnal CO.,LTD | Excel PharmaStudies Inc  | Fidelity Asia Ventures | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP  | Fisher Clinical Services (Beijing) Co,.LTD | Fountain Medical Development LTD | Fudan University | GB（General Biologic) | Gene Tech (Shanghai) Co. Ltd. | Genetimes Technology, Inc.  | GlaxoSmithKline (GSK)  | GleneaglesCRC Pte Ltd | GleneaglesCRC Pte Ltd | GVK Biosciences Private Limited | H&Q AP Biotech Mgmt.Corp | Hays Pharma  | Henan Topfond Pharmaceutical Co.,LTD  | Huadong Medicine | Huntingdon Life Sciences | ICON Clinical Research  | INC Research | Interfax China | Jiangsu Hansoh Pharmaceutical Co., Ltd  | Jiangsu ZW Pharmaceutical Co., Ltd. | Johnson & Johnson  | Jointown Group Co. | Kendle International Inc  | Kingmed | Korea Otsuka International Asia Arab  | Kunming Pharmaceutical Corp. | Kunshan Economic & Technical Development Zone | Kunshan Biomedicine Institute  | Legend Capital | Medicilon/MPI Preclinical Research Shanghai | Medicine Economic News | Medifacts International,Inc.  | Kunshan Economic & Technical Development Zone | Medvill Co., Ltd  | Merck & Co, Inc  | Merck Serono China  | Mitsubishi Pharma Research & Development (Beijing) | Mitsubishi Tanabe Pharma Corporation | Myers Bigel Sibley & Sajovec  | Nanjing New & High Tech Industrial Development Zone | Nanjing SiKe Pharmaceutical Co.，Ltd | Nektar Therapeutics | NeuroSolutions Ltd | Nippon Boehringer Ingelheim Co.,Ltd  | NIPPON KAYAKU Co., Ltd. | North China Pharmaceutical Corporation | Novartis Biomedical Research Institute | OrbiMed Asia | Orrick, Herrington & Sutcliffe LLP | ORYBIO CO.,LTD | Perkins Coie LLP | Pharma China | PharmaAsia | PharmaNet Pte Ltd. | Pierre Fabre S.A. Beijing Office | PR Newswire Asia | PRA International-Asia Pacific  | Pricewaterhouse Coopers | QIAGEN Asia | QIAGEN China (Shanghai) Co., Ltd  | ExchangeQualitix Clinical Research Co., Ltd  | Roche Pharma Partnering  | ScinoPharm Taiwan, Ltd. | Sanofi-Aventis | Sanofi-Aventis China R&D Center | Shandong Xinhua Pharmaceutical Co., Ltd. | Shanghai Clinical Research Center | Shanghai Institute of Biological Products | Shanghai International Medical Zone | Shanghai Municipal FDA | SHIONOGI & Co.,Ltd  | Sino-American Pharmaceutical Professionals Association (SAPA) | SIP Bio & Nano Technology Development Co., Ltd | Square Sanders & Dempsey, LLP | State Intellectual Property Office | Sundia MediTech Company, Ltd  | Sunline | ScinoPharm Taiwan, Ltd. | Sequoia Life Sciences,LLC | SGS Life Science Services  | Taiwan Total Management Consulting Ltd. | Takeda Pharmaceutical Company Ltd  | Tebodin (Shanghai) Engineering & Design Co,Ltd | Teva Pharmaceutical Inc. | The US Food and Drug Administration | The US Food and Drug Administration | Tianjin Hi-tech Industry Park (THIP) | Tianjin Pharmaceutical Holdings Co.,Ltd.  | Tigermed Consulting Ltd  | Tripod Preclinical Research Laboratories Inc.  | United Laboratories, Inc.  | UPON-CRO-CHINA | Vermilion Partners | Vidon & Partners  | Vivo Development Ltd.  | Wuhan Biolake Science Park | Wyeth Research  | XenoBiotic Laboratories, Inc.  | Yantai Luye Pharmaceutical Co., Ltd  | Zensun (Shanghai) Sci & Tech Co., Ltd. | Zhejiang Hisoar Pharmaceutical Co.,LTD.  | ZHONG LUN LAW FIRM  | Zhongguancun Life Science Park

A – Z Information

Pudong International Airport is about 45 km from Shanghai Hua Ting Hotel & Towers. ATM cash withdrawal machine is available at the Shanghai Hua Ting Hotel & Towers.

The Cyber Lounge is located directly outside the meeting ballroom. Internet has been provided for your convenience at the Cyber Lounge.

A lounge has been provided to delegates of the “3rd Annual Pharmaceutical & Biotechnology Pioneer Forum 2010” next to themeeting ballroom. There will be a plasma screen set up for announcements, news and for other important notifications.

The Exhibit Hall is located next to the Plenary Session displaying all kinds of technologies, products and services for free visits.

Special rates have been negotiated with the hotel for PBPF2010 participants. Please make your bookings directly with the hotel and indicate that you are attending “3rd Annual Pharmaceutical & Biotechnology Pioneer Forum 2010”..

The registration/information desk will be staffed throughout the event. You may leave items at the desk if needed. 

The business center at the hanghai Hua Ting Hotel & Towers will be open for guests to print, produce copies, etc.

Restrooms are located in the main building of the hotel in the South and North foyers.

All presentations will be available online after the event. You will require your username and password to log in to Genview account and download the presentations. Contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it if you have problems with your log-in.

All the foreigners must obtain an entry visa before proceeding to China. Attendees are strongly recommended to process the application one-month before departure from the country of origin. For those attendees who need visa notification letter, please contact us before August 14 , 2010:

The five-star Expo 2010 official reception hotel within the city's bustling Xu Jia Hui business district in Shanghai, the Hua Ting Hotel & Towers is an exquisite combination of luxury and convenience.

Guests enjoy the hotel's lavish accommodation, wide range of quality restaurants and excellent transport links.

Located off the hotel's lobby, the Garden Court Restaurant serves a sumptuous international buffet. A la carte choices are, of course, also available.

The first-floor newly-refurbished Deli is open 24 hours a day and is perfect for casual dining, serving an a la carte deli selection of meats, cheeses, salads and other tasty snacks.

The newly refurbished Lobby Lounge is the perfect place to relax with friends or to clinch a deal over a drink or coffee and features live entertainment from a Philippine band nightly. The recently-opened Moon View (Guan Yue Tai) rooftop Chinese restaurant is perched on the hotel's 26th floor, offering breathtaking views of the city. It features delicious Cantonese and Shanghainese cuisine.